Individual features of the pharmacokinetics of fludarabin phosphate in the treatment of patients with chronic lymphocytic leukemia
Open Access
- 13 August 2021
- journal article
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 67-77
- https://doi.org/10.37489/2588-0519-2021-2-67-77
Abstract
Fludarabine is a purine antimetabolite with a pronounced immunosuppressive effect. The inhibitory effect of fludarabine depends on its concentration in blood plasma. In addition, the phenotypic characteristics of patients affect the pharmacokinetic and pharmacodynamic profile of the drug, which necessitates a personalized approach to the dosage regimen. The chromatography-mass spectrometric method for the quantitative determination of 2-fluorine in blood plasma was developed for studying the individual parameters of pharmacokinetics of the international non-proprietary name (INN) fludarabine in patients with B-cell chronic lymphocytic leukemia during the standard course. Such method for the quantitative determination of 2-fluorine in blood plasma was developed and validated in accordance with international requirements. Significant individual variability of the main pharmacokinetic parameters in patients with B-cell chronic lymphocytic leukemia with a single oral administration of the drug with INN fludarabine at a dose of 40 mg/m2 was established, so the coefficient of variability Cmax was 42 %, Tmax — 92 %, AUC0-t — 45 %, Kel — 23 %, T1/2 — 26 %. It should be noted that there is a high interindividual variability of fludarabine, for example, 24 hours after taking the study drug, the maximum and minimum plasma concentrations of the fludarabine metabolite 2-fluoro-ara-A in different in patients with B-cell chronic lymphocytic leukemia differed 9 times. Individual variability of pharmacokinetic parameters characterizing absorption (Cmax/AUC0-t) and total clearance of the active metabolite of fludarabine is statistically significantly associated with a combination of gender and anthropometric factors.Keywords
This publication has 10 references indexed in Scilit:
- Pharmacokinetics and Model-Based Dosing to Optimize Fludarabine Therapy in Pediatric Hematopoietic Cell Transplant RecipientsTransplantation and Cellular Therapy, 2017
- Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC–MS/MS for exposure monitoring in hematopoietic cell transplantation conditioningJournal of Chromatography B, 2017
- Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus InfectionsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2015
- Simultaneous determination of fludarabine and clofarabine in human plasma by LC–MS/MSJournal of Chromatography B, 2014
- Improved quantitative method for fludarabine in human plasma by liquid chromatography and tandem mass spectrometryJournal of Chromatography B, 2013
- PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft ExcelComputer Methods and Programs in Biomedicine, 2010
- Pharmaco-metabonomic phenotyping and personalized drug treatmentNature, 2006
- Substrate specific metabolism by polymorphic cytochrome P450 2D6 allelesToxicology in Vitro, 2005
- Personalised medicine for cancer: from drug development into clinical practiceExpert Opinion on Pharmacotherapy, 2005
- Understanding 'Global' Systems Biology: Metabonomics and the Continuum of MetabolismNature Reviews Drug Discovery, 2003